Table 1.
Study Population Characteristics in 2007
| Schizophrenia | Bipolar Disorder | No MH Diagnosis | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Standard Gap | No Gap (LIS) | Standard Gap | No Gap (LIS) | Standard Gap | No Gap (LIS) | |
| Total N | 1,672 | 2,234 | 1,847 | 1,599 | 1,535 | 1,303 |
|
| ||||||
| Age: <65 | 68% | 85% | 68% | 89% | 31% | 63% |
| 65–69 | 13% | 7% | 14% | 5% | 16% | 9% |
| 70–74 | 8% | 4% | 9% | 3% | 15% | 8% |
| 75–79 | 6% | 2% | 5% | 2% | 15% | 8% |
| 80+ | 5% | 2% | 4% | 1% | 24% | 12% |
|
| ||||||
| Gender: Female | 52% | 50% | 66% | 70% | 54% | 52% |
|
| ||||||
| Reached coverage gap threshold in 2007 ($2,400 in total drug spending) | 47% | 75% | 58% | 82% | 33% | 41% |
|
| ||||||
| Reached catastrophic coverage threshold in 2007 ($3,850 in True out-of- pocket costs) ** | 11% | 40% | 13% | 50% | 7% | 13% |
|
| ||||||
| PDC>80% in Q1 2007 | 54.7% | 67.1% | 37.6% | 55.3% | 40.7% | 46.2% |
|
| ||||||
| Mean PDC in Q1 2007 (SD) | 68.13 (37.22) | 77.98 (32.44) | 52.28 (40.60) | 68.38 (37.73) | 51.62 (42.58) | 60.54 (38.78) |
|
| ||||||
| Mean Comorbidity (RxHCC) score (SD) | 1.54 (0.50) | 1.78 (0.59) | 1.34 (0.43) | 1.54 (0.50) | 1.06 (0.40) | 1.29 (0.49) |
**
True out-of-pocket costs include out-of-pocket costs covered by Medicare’s Low Income Subsidy (LIS)